Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.

BACKGROUND: The World Health Organization (WHO) recommends that tuberculosis (TB) patients receive directly observed therapy (DOT). Randomized controlled trials have not consistently shown that this practice improves TB treatment success rates. In Thailand, one of 22 WHO-designated high burden TB co...

Full description

Bibliographic Details
Main Authors: Amornrat Anuwatnonthakate, Pranom Limsomboon, Sriprapa Nateniyom, Wanpen Wattanaamornkiat, Sittijate Komsakorn, Saiyud Moolphate, Navarat Chiengsorn, Samroui Kaewsa-Ard, Potjaman Sombat, Umaporn Siangphoe, Philip A Mock, Jay K Varma
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2518105?pdf=render
_version_ 1818296371464110080
author Amornrat Anuwatnonthakate
Pranom Limsomboon
Sriprapa Nateniyom
Wanpen Wattanaamornkiat
Sittijate Komsakorn
Saiyud Moolphate
Navarat Chiengsorn
Samroui Kaewsa-Ard
Potjaman Sombat
Umaporn Siangphoe
Philip A Mock
Jay K Varma
author_facet Amornrat Anuwatnonthakate
Pranom Limsomboon
Sriprapa Nateniyom
Wanpen Wattanaamornkiat
Sittijate Komsakorn
Saiyud Moolphate
Navarat Chiengsorn
Samroui Kaewsa-Ard
Potjaman Sombat
Umaporn Siangphoe
Philip A Mock
Jay K Varma
author_sort Amornrat Anuwatnonthakate
collection DOAJ
description BACKGROUND: The World Health Organization (WHO) recommends that tuberculosis (TB) patients receive directly observed therapy (DOT). Randomized controlled trials have not consistently shown that this practice improves TB treatment success rates. In Thailand, one of 22 WHO-designated high burden TB countries, patients may have TB treatment observed by a health care worker (HCW), family member, or no one. We studied whether DOT improved TB treatment outcomes in a prospective, observational cohort. METHODS AND FINDINGS: We prospectively collected epidemiologic data about TB patients treated at public and private facilities in four provinces in Thailand and the national infectious diseases hospital from 2004-2006. Public health staff recorded the type of observed therapy that patients received during the first two months of TB treatment. We limited our analysis to pulmonary TB patients never previously treated for TB and not known to have multidrug-resistant TB. We analyzed the proportion of patients still on treatment at the end of two months and with treatment success at the end of treatment according to DOT type. We used propensity score analysis to control for factors associated with DOT and treatment outcome. Of 8,031 patients eligible for analysis, 24% received HCW DOT, 59% family DOT, and 18% self-administered therapy (SAT). Smear-positive TB was diagnosed in 63%, and 21% were HIV-infected. Of patients either on treatment or that defaulted at two months, 1601/1636 (98%) patients that received HCW DOT remained on treatment at two months compared with 1096/1268 (86%) patients that received SAT (adjusted OR [aOR] 3.8; 95% confidence interval [CI] 2.4-6.0) and 3782/3987 (95%) patients that received family DOT (aOR 2.1; CI, 1.4-3.1). Of patients that had treatment success or that defaulted at the end of treatment, 1369/1477 (93%) patients that received HCW DOT completed treatment compared with 744/1074 (69%) patients that received SAT (aOR 3.3; CI, 2.4-4.5) and 3130/3529 (89%) patients that received family DOT (aOR 1.5; 1.2-1.9). The benefit of HCW DOT compared with SAT was similar, but smaller, when comparing patients with treatment success to those with death, default, or failure. CONCLUSIONS: In Thailand, two months of DOT was associated with lower odds of default during treatment. The magnitude of benefit was greater for DOT provided by a HCW compared with a family member. Thailand should consider increasing its use of HCW DOT during TB treatment.
first_indexed 2024-12-13T04:02:29Z
format Article
id doaj.art-9394b8cccb5147d2adbdbeb047349233
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T04:02:29Z
publishDate 2008-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-9394b8cccb5147d2adbdbeb0473492332022-12-22T00:00:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032008-01-0138e308910.1371/journal.pone.0003089Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.Amornrat AnuwatnonthakatePranom LimsomboonSriprapa NateniyomWanpen WattanaamornkiatSittijate KomsakornSaiyud MoolphateNavarat ChiengsornSamroui Kaewsa-ArdPotjaman SombatUmaporn SiangphoePhilip A MockJay K VarmaBACKGROUND: The World Health Organization (WHO) recommends that tuberculosis (TB) patients receive directly observed therapy (DOT). Randomized controlled trials have not consistently shown that this practice improves TB treatment success rates. In Thailand, one of 22 WHO-designated high burden TB countries, patients may have TB treatment observed by a health care worker (HCW), family member, or no one. We studied whether DOT improved TB treatment outcomes in a prospective, observational cohort. METHODS AND FINDINGS: We prospectively collected epidemiologic data about TB patients treated at public and private facilities in four provinces in Thailand and the national infectious diseases hospital from 2004-2006. Public health staff recorded the type of observed therapy that patients received during the first two months of TB treatment. We limited our analysis to pulmonary TB patients never previously treated for TB and not known to have multidrug-resistant TB. We analyzed the proportion of patients still on treatment at the end of two months and with treatment success at the end of treatment according to DOT type. We used propensity score analysis to control for factors associated with DOT and treatment outcome. Of 8,031 patients eligible for analysis, 24% received HCW DOT, 59% family DOT, and 18% self-administered therapy (SAT). Smear-positive TB was diagnosed in 63%, and 21% were HIV-infected. Of patients either on treatment or that defaulted at two months, 1601/1636 (98%) patients that received HCW DOT remained on treatment at two months compared with 1096/1268 (86%) patients that received SAT (adjusted OR [aOR] 3.8; 95% confidence interval [CI] 2.4-6.0) and 3782/3987 (95%) patients that received family DOT (aOR 2.1; CI, 1.4-3.1). Of patients that had treatment success or that defaulted at the end of treatment, 1369/1477 (93%) patients that received HCW DOT completed treatment compared with 744/1074 (69%) patients that received SAT (aOR 3.3; CI, 2.4-4.5) and 3130/3529 (89%) patients that received family DOT (aOR 1.5; 1.2-1.9). The benefit of HCW DOT compared with SAT was similar, but smaller, when comparing patients with treatment success to those with death, default, or failure. CONCLUSIONS: In Thailand, two months of DOT was associated with lower odds of default during treatment. The magnitude of benefit was greater for DOT provided by a HCW compared with a family member. Thailand should consider increasing its use of HCW DOT during TB treatment.http://europepmc.org/articles/PMC2518105?pdf=render
spellingShingle Amornrat Anuwatnonthakate
Pranom Limsomboon
Sriprapa Nateniyom
Wanpen Wattanaamornkiat
Sittijate Komsakorn
Saiyud Moolphate
Navarat Chiengsorn
Samroui Kaewsa-Ard
Potjaman Sombat
Umaporn Siangphoe
Philip A Mock
Jay K Varma
Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.
PLoS ONE
title Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.
title_full Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.
title_fullStr Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.
title_full_unstemmed Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.
title_short Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.
title_sort directly observed therapy and improved tuberculosis treatment outcomes in thailand
url http://europepmc.org/articles/PMC2518105?pdf=render
work_keys_str_mv AT amornratanuwatnonthakate directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT pranomlimsomboon directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT sriprapanateniyom directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT wanpenwattanaamornkiat directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT sittijatekomsakorn directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT saiyudmoolphate directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT navaratchiengsorn directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT samrouikaewsaard directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT potjamansombat directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT umapornsiangphoe directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT philipamock directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand
AT jaykvarma directlyobservedtherapyandimprovedtuberculosistreatmentoutcomesinthailand